IDEAYA Biosciences’ Post

💥The following paper: "Investigational Drug Treatments for Triple-Negative Breast Cancer" is published in the Journal of Personalized Medicine MDPI at: https://lnkd.in/gUTce5aJ We invite you to read this paper at the above link. And also hope that you could consider JPM (https://lnkd.in/g3jxwN_H) when submitting your next paper. #personalizedmedicine #precisionmedicine #breastcancer

FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology Annual Meeting #stockmarket #stocks #investing #businessnews #trading #daytrading #clinicaltrial

First-in-human clinical data of our anti-IGSF8 program GV20-0251 was presented at #ESMO2024 today. We are one step closer to bringing a potential therapy for cancer patients. Read more here: https://lnkd.in/ehA_nhw7 #Oncology #ESMO2024 #GV20

Exciting insights from the AACR 2024 preview! 🌟 Key clinical highlights and setbacks provide a glimpse into the evolving landscape of cancer therapy development. Looking forward to seeing advancements in selective PARP1 inhibition, anti-TROP2 conjugates, and KRAS inhibition. Stay tuned for more updates! #AACR2024 #CancerResearch #MedicalAdvancements 🚀🔬

A paper in the Journal of Pharmacokinetics and Pharmacodynamics used a PBPK model to quantify the affects of drug interactions with combination breast cancer therapy (docetaxel, cyclophosphamide, and epirubicin). PBPK = physiologically based pharmacokinetic Link to Abstract: https://bit.ly/4cJlvP4 | #DrugDrugInteraction #CancerTreatments #Docetaxel #Cyclophosphamide #Epirubicin #PharmacokineticModels Springer Nature Group

Results of Tropion lung study

𝙀𝙛𝙛𝙞𝙘𝙖𝙘𝙮 𝙖𝙣𝙙 𝙨𝙖𝙛𝙚𝙩𝙮 𝙤𝙛 𝙖𝙣𝙡𝙤𝙩𝙞𝙣𝙞𝙗 𝙥𝙡𝙪𝙨 𝙥𝙚𝙣𝙥𝙪𝙡𝙞𝙢𝙖𝙗 𝙖𝙨 𝙨𝙚𝙘𝙤𝙣𝙙-𝙡𝙞𝙣𝙚 𝙩𝙧𝙚𝙖𝙩𝙢𝙚𝙣𝙩 𝙛𝙤𝙧 𝙨𝙢𝙖𝙡𝙡 𝙘𝙚𝙡𝙡 𝙡𝙪𝙣𝙜 𝙘𝙖𝙣𝙘𝙚𝙧: 𝘼 𝙢𝙪𝙡𝙩𝙞𝙘𝙚𝙣𝙩𝙚𝙧, 𝙤𝙥𝙚𝙣-𝙡𝙖𝙗𝙚𝙡, 𝙨𝙞𝙣𝙜𝙡𝙚-𝙖𝙧𝙢 𝙥𝙝𝙖𝙨𝙚 𝙄𝙄 𝙩𝙧𝙞𝙖𝙡. A combination of #anlotinib and #penpulimab is a promising and safe #secondlinetherapy for patients with #smallcelllungcancer who face instances of first-line standard #chemotherapy failures. Read more in this #CancerPathogenesisAndTherapy article:  https://lnkd.in/ezydRnfu

First-line treatment with ivonescimab (AK112; SMT112) monotherapy led to a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared with pembrolizumab (Keytruda) monotherapy in patients with locally advanced or metastatic, PD-L1–positive non–small cell lung cancer (NSCLC), meeting the primary end point of the phase 3 HARMONi-2 trial (NCT05499390)OncLive https://lnkd.in/gj-HGWQP

🌟💬 Xtalks Spotlight: To gain insights into the top oncology clinical trial trends shared at ESMO, we spoke with two experts from Fortrea, Dr. Laura Vidal Boixader and Dr. Ken Morrison. Discover key takeaways from the influential 2023 ESMO conference, where groundbreaking breakthroughs and patient-centered dialogues were at the forefront. ⏩ Watch + read the full Spotlight feature: https://buff.ly/3Hkk23d #Cancer #Oncology #ClinicalTrials #XtalksSpotlight

American Society of Clinical Oncology (ASCO) attendees, what were some of the most interesting things you saw at this year's conference? Please share. We'd love to know what caught your attention. In the meantime, Clinical Trials Arena put together a top 10 list of breaking research at the conference. Any significant research to add to the list? #lungcancer #cancerresearch #lungcancerawareness #asco2024 https://lnkd.in/gumpz_WX